|
DK1859798T3
(en)
*
|
2001-03-29 |
2016-03-21 |
Lilly Co Eli |
N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
|
|
BR0211561A
(pt)
*
|
2001-08-03 |
2004-11-30 |
Upjohn Co |
Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos
|
|
DK1523486T3
(da)
|
2002-06-21 |
2008-03-03 |
Suven Life Sciences Ltd |
Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
|
|
EP1546105A1
(en)
*
|
2002-07-17 |
2005-06-29 |
Lek Pharmaceutical and Chemical Co. D.D. |
Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
|
|
KR101025633B1
(ko)
|
2002-09-19 |
2011-03-30 |
일라이 릴리 앤드 캄파니 |
오피오이드 수용체 안타고니스트로서의 디아릴 에테르
|
|
US7645886B2
(en)
*
|
2002-12-20 |
2010-01-12 |
Ciba Specialty Corporation |
Synthesis of amines and intermediates for the synthesis thereof
|
|
CN1756746A
(zh)
|
2003-03-07 |
2006-04-05 |
伊莱利利公司 |
作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
|
|
US7396943B2
(en)
|
2003-03-07 |
2008-07-08 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
DE602004000260T2
(de)
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
CN1894240A
(zh)
|
2003-12-22 |
2007-01-10 |
伊莱利利公司 |
阿片受体拮抗剂
|
|
EP1727788B1
(en)
|
2004-03-12 |
2010-07-28 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
JP2007529523A
(ja)
|
2004-03-15 |
2007-10-25 |
イーライ リリー アンド カンパニー |
肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
|
|
CA2557794A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
LT2502911T
(lt)
*
|
2004-06-24 |
2017-09-11 |
Vertex Pharmaceuticals Incorporated |
Atp surišančios kasetės transporterių moduliatoriai
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
ATE474833T1
(de)
|
2004-09-22 |
2010-08-15 |
Janssen Pharmaceutica Nv |
Inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
JP5170742B2
(ja)
*
|
2005-12-28 |
2013-03-27 |
積水メディカル株式会社 |
凝集測定用試薬及び凝集測定方法
|
|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CN101400677A
(zh)
*
|
2006-01-06 |
2009-04-01 |
阿斯利康(瑞典)有限公司 |
化合物
|
|
US8232298B2
(en)
|
2006-03-22 |
2012-07-31 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between MDM2 and P53
|
|
WO2007107545A1
(en)
|
2006-03-22 |
2007-09-27 |
Janssen Pharmaceutica N.V. |
Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
US8017785B2
(en)
|
2006-05-09 |
2011-09-13 |
Astrazeneca Ab |
Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
ES2534899T3
(es)
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
EP2209380A4
(en)
*
|
2007-10-09 |
2011-09-14 |
Mark T Hamann |
METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
|
|
EP2231160B1
(en)
|
2007-12-04 |
2013-08-14 |
Merck Sharp & Dohme Corp. |
Tryptamine sulfonamides as 5-ht6 antagonists
|
|
EP2508177A1
(en)
|
2007-12-12 |
2012-10-10 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
AU2009214724A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Organix Inc. |
Indole compounds and methods of use thereof
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
TWI476189B
(zh)
*
|
2009-02-04 |
2015-03-11 |
Janssen Pharmaceutica Nv |
用作抗癌劑之吲哚衍生物
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
EP2464227A4
(en)
*
|
2009-08-10 |
2013-02-20 |
Galenea Corp |
COMPOUNDS AND METHODS OF USE
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
*
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
|
JP2015512383A
(ja)
*
|
2012-03-20 |
2015-04-27 |
アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． |
Ｃｎｓ疾患の処置のためのベンジルアミンのスルホンアミド誘導体
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
*
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
US20160038484A1
(en)
*
|
2013-04-03 |
2016-02-11 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
KR20170063954A
(ko)
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
TW201630881A
(zh)
|
2014-12-12 |
2016-09-01 |
Ｈ 朗德貝克公司 |
用於生產艾達魯吡啶之方法
|
|
US10022355B2
(en)
|
2015-06-12 |
2018-07-17 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
|
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|
|
WO2017067670A1
(en)
|
2015-10-23 |
2017-04-27 |
Pharmathen S.A. |
A novel process for the preparation of tryptamines and derivatives thereof
|
|
WO2017174691A1
(en)
|
2016-04-08 |
2017-10-12 |
H. Lundbeck A/S |
A process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
US10383849B2
(en)
*
|
2016-04-26 |
2019-08-20 |
H. Lundbeck A/S |
Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
BR112019001145A2
(pt)
|
2017-05-24 |
2019-04-30 |
H. Lundbeck A/S |
combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
|
|
EP4417596B1
(en)
|
2017-11-06 |
2026-04-29 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a-beta-42 oligomer formation
|
|
WO2020179859A1
(ja)
|
2019-03-06 |
2020-09-10 |
第一三共株式会社 |
ピロロピラゾール誘導体
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
WO2021226416A1
(en)
|
2020-05-08 |
2021-11-11 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
WO2022047583A1
(en)
*
|
2020-09-02 |
2022-03-10 |
Magicmed Industries Inc. |
Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder
|
|
WO2022060763A2
(en)
*
|
2020-09-17 |
2022-03-24 |
Merck Sharp & Dohme Corp. |
Modified imidazopyridines as glucosylceramide synthase inhibitors
|
|
KR20230157342A
(ko)
|
2021-02-12 |
2023-11-16 |
인베릭 바이오사이언시스 캐나다 인크. |
다중 치환기 실로시빈 유도체 및 사용 방법
|
|
AU2022229037A1
(en)
*
|
2021-03-02 |
2023-09-28 |
Mindset Pharma Inc. |
Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
|
|
EP4337220A4
(en)
*
|
2021-05-11 |
2025-07-02 |
Saint Josephs Univ |
SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
|
|
CA3218110A1
(en)
|
2021-05-25 |
2022-12-01 |
Majed Fawaz |
New n,n-dimethyltryptamine salts and crystalline salt forms
|
|
MX2023014630A
(es)
|
2021-06-08 |
2024-01-30 |
Atai Therapeutics Inc |
Activadores de dimetoxifenilalquilamina de receptores de serotonina.
|
|
AU2022287974A1
(en)
|
2021-06-09 |
2024-01-04 |
Atai Therapeutics, Inc. |
Novel prodrugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
EP4457203A4
(en)
|
2021-12-27 |
2025-12-17 |
Atai Therapeutics Inc |
AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
|
|
WO2023129956A2
(en)
|
2021-12-30 |
2023-07-06 |
ATAI Life Sciences AG |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
WO2023173196A1
(en)
|
2022-03-18 |
2023-09-21 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
US12343319B2
(en)
|
2023-05-01 |
2025-07-01 |
Atai Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
US20250243160A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|